Dynavax Technologies Corporation (FRA:DYF1)

Market Cap	1.09B
Revenue (ttm)	281.70M
Net Income (ttm)	-36.99M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	14.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	34
Open	9.09
Previous Close	8.78
Day's Range	8.97 - 9.10
52-Week Range	7.65 - 13.57
Beta	n/a
RSI	49.32
Earnings Date	Feb 20, 2026

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 405
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DYF1

Financial Performance

Financial numbers in USD